Dr. OZGE GUMUSAY

Education

• 2023Acıbadem University Faculty of Medicine / Professor
• 2022Acıbadem University Faculty of Medicine / Associate Professor
• 2017Gaziosmanpaşa University Faculty of Medicine / Associate Professor
• 2014Gazi University Faculty of Medicine Medical Oncology
• 2010Gazi University Faculty of Medicine Internal Medicine
• 2005Hacettepe University Faculty of Medicine

Experience

• 2022Acıbadem Health Group
• 2021Stanford University Comprehensive Cancer Center, Palo Alto, California, (Visiting Observer)
• 2019 – 2021UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, (Breast Cancer Oncology)
• 2017 – 2019Gaziosmanpaşa University Faculty of Medicine, Medical Oncology Specialist, Associate Professor
• 2014 – 2017Gaziosmanpaşa University Faculty of Medicine, Medical Oncology Specialist, Assistant Professor
• 2010 – 2014Gazi University Faculty of Medicine, Medical Oncology Sub-branch Research Assistant
• 2006 – 2010Gazi University Faculty of Medicine, Internal Medicine Research Assistant

Memberships

• American Society of Clinical Oncology (ASCO)
• The European Society of Medical Oncology (ESMO)
• Turkish Medical Oncology Association (TTOD)

PUBLICATIONS

• CDK4/6 inhibitors: Mechanisms of resistance and potential biomarkers of responsiveness in breast cancerFuture Oncology, 2022 Mar;18(9):1143-1157. Cetin B, Wabl CA, Gumusay O.
• Immunotherapy Toxicity: identification and managementBreast Cancer Res Treat 2022 Feb;192(1):1-17. Gumusay O, Callan J, Rugo HS.
• Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy.Front. Oncol., 15 March 2022. ( share first authorship) Magbanua MJ, Gumusay O, Kurzrock R, vant Veer LJ, Rugo HS.
• The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two casesBreast. 2022 Apr 2;63:149-156. Gumusay O, Huppert LA, Behr SC, Rugo HS.
• Emerging treatment strategies for metastatic triple-negative breast cancer.Therapeutic Advances in Medical Oncology. January 2022. Huppert LA, Gumusay O, Rugo HS.
• Trials of Immunotherapy in Triple Negative Breast Cancer.Curr Breast Cancer Rep 13, 171185 (2021). Gumusay O, Wabl, CA, Rugo HS.
• Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med 2020 Jun 25;382(26):e108. Cetin B, Gumusay O.
• Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology.Am Soc Clin Oncol Educ Book. 2020 May;40:e292-e308. Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS.
• Factors Influencing Chemotherapy Goal Perception in Newly Diagnosed Cancer PatientsJ Cancer Educ. 2016 Jun;31(2):308-13. Gumusay O, Cetin B, Benekli M, Gurcan G, Ilhan MN, Bostankolu B, Ozet A, Uner A, Coskun U, Buyukberber S.
• Discordances in HER2 status between primary gastric cancer and corresponding metastatic sitesJapanese Journal of Clinical Oncology. 2015 May; 45(5), 416-421. Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, Buyukberber S.